Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.
Arati Desai, MD, co-director of the University of Pennsylvania Brain Tumor Cancer Program Center and assistant professor of Clinical Medicine, at the Perelman School of Medicine, University of Pennsylvania, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma (AA).
When treatment advances are sought, the therapies that are needed are those that improve upon the standard of care. There are good agents available for the treatment of AA, but the drugs are older and, at times, cause intolerable toxicity and offer limited benefit.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More